RT Journal Article
SR Electronic
T1 Intrafamilial Exposure to SARS-CoV-2 Induces Cellular Immune Response without Seroconversion
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.06.21.20132449
DO 10.1101/2020.06.21.20132449
A1 Floriane Gallais
A1 Aurélie Velay
A1 Marie-Josée Wendling
A1 Charlotte Nazon
A1 Marialuisa Partisani
A1 Jean Sibilia
A1 Sophie Candon
A1 Samira Fafi-Kremer
YR 2020
UL http://medrxiv.org/content/early/2020/06/22/2020.06.21.20132449.abstract
AB Background In the background of the current COVID-19 pandemic, serological tests are being used to assess past infection and immunity against SARS-CoV-2. This knowledge is paramount to determine the transmission dynamics of SARS-CoV-2 through the post pandemic period. Several individuals belonging to households with an index COVID-19 patient, reported symptoms of COVID-19 but discrepant serology results.Methods Here we investigated the humoral and cellular immune responses against SARS-CoV-2 in seven families, including nine index patients and eight contacts, who had evidence of serological discordances within the households. Ten unexposed healthy donors were enrolled as controls.Results All index patients recovered from a mild COVID-19. They all developed anti-SARS-CoV-2 antibodies and a significant T cell response detectable up to 69 days after symptom onset. Six of the eight contacts reported COVID-19 symptoms within 1 to 7 days after the index patients but all were SARS-CoV-2 seronegative. Six out of eight contacts developed a SARS-CoV-2-specific T cell response against structural and/or accessory proteins that lasts up to 80 days post symptom onset suggesting a past SARS-CoV-2 infection.Conclusion Exposure to SARS-CoV-2 can induce virus-specific T cell responses without seroconversion. T cell responses may be more sensitive indicators of SARS-Co-V-2 exposure than antibodies. Our results indicate that epidemiological data relying only on the detection of SARS-CoV-2 antibodies may lead to a substantial underestimation of prior exposure to the virus.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was supported by the Strasbourg University Hospital (COVID-HUS study-HUS N 7760)Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All the participants gave written informed consent for research according to protocols approved by the institutional review board of Strasbourg University Hospitals (CE-2020-34)All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.Yesdata can be provided by the corresponding authorCOVID-19Corona Virus Disease 2019SARS-CoV-2severe acute respiratory syndrome coronavirus 2HCoVhuman coronavirusesRT-PCRreverse transcriptase-polymerase chain reactionRBDReceptor Binding DomainIFNinterferonPBMCsPeripheral blood Mononuclear CellsHDHealthy Donors